pioglitazone has been researched along with rivoglitazone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, HS; Goldberg, RB; Merante, D; Rosenstock, J; Triscari, J; Truitt, KE; Wang, AC | 1 |
| Funahashi, T; Hirata, A; Hiuge-Shimizu, A; Kihara, S; Maeda, N; Nakamura, K; Nakatsuji, H; Okuno, A; Shimomura, I | 1 |
| Asami, T; Chan, JC; Ko, GT; Kong, AP; Lee, KF; Leung, GT; Ohwada, S; Ozaki, R; Saito, H; Wong, CK; Yamasaki, A; Yeung, CY | 1 |
| Choi, Y; Chou, HS; Merante, D; Moberly, JB; Mun, Y; Pfützner, A; Truitt, KE | 1 |
3 trial(s) available for pioglitazone and rivoglitazone
| Article | Year |
|---|---|
A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones; Treatment Outcome; Young Adult | 2010 |
A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Middle Aged; Pioglitazone; PPAR gamma; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.
Topics: Biomarkers, Pharmacological; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipid Metabolism; Male; Middle Aged; Pioglitazone; Single-Blind Method; South Africa; Thiazolidinediones; Treatment Outcome; United States | 2012 |
1 other study(ies) available for pioglitazone and rivoglitazone
| Article | Year |
|---|---|
Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue, White; Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Calgranulin A; Cytokines; Disease Models, Animal; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Thiazolidinediones; Time Factors | 2011 |